Prime Medicine
PRME
76 hedge funds and large institutions have $512M invested in Prime Medicine in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 7 closing their positions.
383% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 6
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
15% more funds holding
Funds holding: 66 → 76 (+10)
0.41% more ownership
Funds ownership: 42.51% → 42.92% (+0.41%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
33% less capital invested
Capital invested by funds: $768M → $512M (-$256M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$8.33M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$8.3M |
| 3 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$5.69M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.6M |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$2.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.53M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$1.66M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.3M |
| 5 |
PMEF
Point72 Middle East FZE
Dubai,
United Arab Emirates
|
-$699K |
PRME Hedge Fund Activity: Q1 2023 in Review
76 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2023, worth a combined $512M — down 33% from $768M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PRME positions and 7 closed out — a net gain of 11 holders — while 29 added to existing stakes and 6 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $8.33M. The largest seller was T. Rowe Price Associates, cutting an estimated $24M.
- 76 institutional investors held Prime Medicine (PRME) as of Q1 2023, up from 66 in Q4 2022.
- Funds reported $512M of Prime Medicine stock for Q1 2023, down 33% quarter-over-quarter.
- 18 funds opened new Prime Medicine positions in Q1 2023 and 7 closed out, a net change of +11 holders.
- The largest Prime Medicine buyer in Q1 2023 was Nikko Asset Management Americas, an estimated $8.33M added.
- The largest Prime Medicine seller in Q1 2023 was T. Rowe Price Associates, an estimated $24M sold.
Based on aggregated 13F filings for Q1 2023.